Om

Poxel SA is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases and related liver disorders. The company’s work centers on therapies for type 2 diabetes, non-alcoholic steatohepatitis (NASH), and other conditions linked to metabolic dysfunction. Its current product portfolio includes imeglimin, marketed in Japan for type 2 diabetes, as well as investigational programs such as PXL770 and PXL065 for liver and metabolic indications. Poxel SA operates in the biotechnology and pharmaceuticals space, combining drug discovery, clinical development, and partnership-based commercialization to address serious chronic diseases. Headquartered in Lyon, France, the company serves a specialized role in the global biopharmaceutical market by advancing targeted therapies for complex metabolic conditions.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I POXEL MED ENDAVU: Køb Poxel ($POXEL) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Poxel, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.